Ozempic vs Wegovy

Ozempic and Wegovy contain the same active ingredient -- semaglutide, manufactured by Novo Nordisk -- but they are approved by the FDA for different uses. Ozempic was approved in 2017 for the treatment of type 2 diabetes and to reduce cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease. Wegovy was approved in 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related condition. In 2024, Wegovy received an additional approval for reducing the risk of major adverse cardiovascular events, based on the results of the SELECT trial.

The key practical difference is dosing. According to their respective prescribing information, Ozempic is available in doses up to 2 mg administered once weekly. Wegovy's dosing schedule reaches higher levels of semaglutide; as of March 2026, the FDA approved Wegovy HD at a maximum dose of 7.2 mg once weekly. The higher doses available under the Wegovy label reflect the dosing studied in the weight management clinical trial program.

Because these are the same molecule with different approved indications, the distinction matters primarily for insurance coverage and prescribing. A prescription for Ozempic is typically covered under a pharmacy benefit for type 2 diabetes, while Wegovy may be covered under weight management or obesity benefits, which vary significantly by insurer. Patients should not switch between these medications without consulting their prescribing physician, as the dosing schedules, titration protocols, and approved uses differ. Talk to your doctor and insurance provider about which prescription is appropriate for your specific medical situation.